KD Logo

A Guide To The Risks Of Investing In Amicus Therapeutics Inc (FOLD)

In a filing, Amicus Therapeutics Inc revealed its President and CEO Campbell Bradley L unloaded Company’s shares for reported $75000.0 on Jun 03 ’24. In the deal valued at $10.00 per share,7,500 shares were sold. As a result of this transaction, Campbell Bradley L now holds 886,654 shares worth roughly $8.91 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Campbell Bradley L sold 7,500 shares, generating $75,524 in total proceeds. Upon selling the shares at $10.07, the President and CEO now owns 886,654 shares.

Before that, Campbell Bradley L sold 7,500 shares. Amicus Therapeutics Inc shares valued at $87,496 were divested by the President and CEO at a price of $11.67 per share. As a result of the transaction, Campbell Bradley L now holds 886,654 shares, worth roughly $8.91 million.

Wells Fargo initiated its Amicus Therapeutics Inc [FOLD] rating to an Overweight in a research note published on May 30, 2024; the price target was $18. A number of analysts have revised their coverage, including Guggenheim’s analysts, who increased its forecast for the stock in mid May from “a Neutral” to “a Buy”. Morgan Stanley also remained covering FOLD and has increased its forecast on December 19, 2023 with a “an Overweight” recommendation from previously “an Equal-weight” rating. Morgan Stanley started covering the stock on September 09, 2022. It rated FOLD as “an Equal-weight”.

Price Performance Review of FOLD

On Monday, Amicus Therapeutics Inc [NASDAQ:FOLD] saw its stock unchanged to $10.05. Over the last five days, the stock has gained 0.20%. Amicus Therapeutics Inc shares have fallen nearly -29.18% since the year began. Nevertheless, the stocks have fallen -20.36% over the past one year. While a 52-week high of $14.57 was reached on 01/02/24, a 52-week low of $9.02 was recorded on 05/13/24. SMA at 50 days reached $10.32, while 200 days put it at $11.71. A total of 1.6 million shares were traded, compared to the trading of 1.21 million shares in the previous session.

Levels Of Support And Resistance For FOLD Stock

The 24-hour chart illustrates a support level at 9.87, which if violated will result in even more drops to 9.69. On the upside, there is a resistance level at 10.15. A further resistance level may holdings at 10.25. The Relative Strength Index (RSI) on the 14-day chart is 50.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 37.90%. Stochastics %K at 68.01% indicates the stock is a holding.

Most Popular